



2021 Financial Calendar

Paris, France, April 23, 2021 (5.45 pm CEST) – Advicenne (Euronext: ADVIC) today publishes its indicative financial calendar for the financial year 2021.

Event	Date*
Annual results 2020	Wednesday, April 28, 2021
General Meeting	Monday, June 14, 2021
Half-Year Results 2021	Thursday, September 30, 2021

Financial year end on December 31

** Subject to change. Publication after market close.*

About Advicenne

Advicenne (Euronext: ADVIC) is a pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead drug candidate is currently in late-stage clinical trials for two kidney diseases: the renal tubular acidosis and cystinuria. ADV7103 has recently received a positive CHMP opinion for the treatment of dRTA.

Headquartered in Paris, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was cross-listed on the Euronext Brussels stock exchange in 2019.

For additional information see: www.advicenne.com

Contacts:

Advicenne

David Solomon, Chairman
+33 (0)4 66 05 54 20
Email: investors@advicenne.com

Financial communications

NewCap
Dusan Oresansky, Emmanuel Huynh
+33 (0)1 44 71 94 94

Press Relations

NewCap
Nicolas Merigeau
+33 (0)1 44 71 94 98

Email: advicenne@newcap.eu

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Advicenne, which shall not be considered per se as historical facts. Such statements include projections and estimates, and the hypotheses on

which these are based, as well as observations relating to operations, ongoing projects, objectives, the development of products and their future performance, and expectations regarding financial results.

In some cases, forward-looking statements can be identified by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets" or similar words. Although the management of Advicenne believes that these forward-looking statements are reasonably made, investors should be aware that they are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In particular, the expectations of Advicenne could be affected by, among other things, uncertainties involved in the placing on the market and commercialization of Advicenne products or any other risks and uncertainties developed or identified in any public documents filed by Advicenne with the French Financial Markets Authority (*Autorité des marchés financiers* (AMF)), including those listed in Chapter 4, "Risk Factors," of its universal registration document, filed with the latter on December 22, 2020. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be "accurate, precise and fairly presented"), Advicenne disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.